Digital Phenotyping for Detecting Depression Severity in a Large Payor-Provider System: Retrospective Study of Speech and Language Model Performance.

Bradley Karlin^1,2, Doug Henry¹, Ryan Anderson¹, Salvatore Cieri¹, Michael Aratow³, Elizabeth Shriberg³, Michelle Hoy³

¹Highmark Health, 120 Fifth Avenue, Fifth Avenue Place, Pittsburgh, PA, 15222-3099, United States, 1 (412) 544-7000.

²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

³Ellipsis Health, 548 Market Street, PMB 49051, San Francisco, CA, 94104-5401, United States, 1 800-410-5383.

PubMed PMC DOI PDF

Abstract

BACKGROUND: There is considerable need to improve and increase the detection and measurement of depression. The use of speech as a digital biomarker of depression represents a considerable opportunity for transforming and accelerating depression identification and treatment; however, research to date has primarily consisted of small-sample feasibility or pilot studies incorporating highly controll…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.